Stock Events

Stock Events

Peptron

₩145,500

9

+₩3,500+2.46% 06:19 Today

Statistics

Day High

148,400

Day Low

142,600

52W High

392,500

52W Low

98,000

Volume

90,295

Avg. Volume

231,005

Mkt Cap

3.38T

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

13MayExpected

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

-148

-147

-147

-147

Expected EPS

N/A

Actual EPS

N/A

Financials

-245.33%Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

5.63BRevenue

-13.82BNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Biogen is a biopharmaceutical company that competes with Peptron in the development of therapies for neurological diseases, including Parkinson's disease, which is a key area of focus for Peptron.

Roche Holding AG is involved in the research and development of pharmaceutical products for various health issues, including neurological disorders, making it a competitor in the neurodegenerative disease market.

Novartis AG competes with Peptron in the healthcare sector, particularly in the development of treatments for chronic diseases, including neurological conditions.

Pfizer is a global pharmaceutical company that develops medicines and vaccines for a wide range of conditions, including neurological diseases, competing with Peptron's research and development focus.

Merck & Co., Inc. is a healthcare company that produces pharmaceuticals and vaccines for various diseases, including those related to neurology, making it a competitor in the field.

AbbVie is a biopharmaceutical company that has a strong presence in the neuroscience sector, including the development of treatments for Parkinson's disease, directly competing with Peptron.

Eli Lilly and Company is engaged in the discovery, development, and marketing of pharmaceutical products, including for neurological disorders, positioning it as a competitor.

Amgen is a biotechnology company focused on developing novel therapies for serious illnesses, including neurodegenerative diseases, competing with Peptron in this research area.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company that manufactures generic and specialty medicines, including for neurological conditions, making it a competitor.

AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a broad range of therapies, including for neurological diseases, competing with Peptron in the healthcare market.

About

Peptron, Inc. specializes in the creation of peptide-based pharmaceuticals designed to manage chronic health conditions. The company's technological expertise encompasses advanced long-acting drug delivery systems and SmartDepot, an ultrasonic spray-drying technique utilized for developing sustained-release injectable microsphere drug formulations. Their research and development pipeline features several key products: Luphere Depot, which addresses prostate cancer, endometriosis, uterine fibroids, and puberty-related issues; SR-Octreotide (PT201) for treating acromegaly; SR-Exenatide (PT302) for type 2 diabetes; and SR-Exenatide (PT320), which is aimed at Parkinson's and Alzheimer's diseases. Founded in 1997, Peptron, Inc. is headquartered in Daejeon, South Korea.

Show more...

CEO

Ho-Il Choi

Employees

163

Country

South Korea

ISIN

KR7087010005

Listings

0 Comments

Share your thoughts

FAQ

What is Peptron stock price today?▼

The current price of 087010.KQ is ₩145,500 KRW — it has increased by +2.46% in the past 24 hours. Watch Peptron stock price performance more closely on the chart.

What is Peptron stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on KOSDAQ exchange Peptron stocks are traded under the ticker 087010.KQ.

Is Peptron stock price growing?▼

087010.KQ stock has fallen by -0.68% compared to the previous week, the month change is a -18.53% fall, over the last year Peptron has showed a -52.76% decrease.

What is Peptron market cap?▼

Today Peptron has the market capitalization of 3.38T

What is Peptron revenue for the last year?▼

Peptron revenue for the last year amounts to 5.63B KRW.

What is Peptron net income for the last year?▼

087010.KQ net income for the last year is -13.82B KRW.

How many employees does Peptron have?▼

As of September 23, 2026, the company has 163 employees.

In which sector is Peptron located?▼

Peptron operates in the Health & Wellness sector.

When did Peptron complete a stock split?▼

The last stock split for Peptron was on July 25, 2018 with a ratio of 1:1.

Where is Peptron headquartered?▼

Peptron is headquartered in Daejeon, South Korea.